RenovoRx (RNXT) Projected to Post Quarterly Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is anticipated to release its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect RenovoRx to post earnings of ($0.08) per share and revenue of $0.47 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.42 million. RenovoRx had a negative return on equity of 119.77% and a negative net margin of 994.48%.During the same quarter in the prior year, the firm posted ($0.40) earnings per share. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Trading Down 4.1%

Shares of RNXT opened at $0.89 on Thursday. RenovoRx has a 52 week low of $0.70 and a 52 week high of $1.45. The firm has a market cap of $40.09 million, a price-to-earnings ratio of -2.78 and a beta of 1.00. The stock has a 50 day moving average of $0.94 and a 200-day moving average of $0.96.

Institutional Trading of RenovoRx

A number of large investors have recently modified their holdings of RNXT. XTX Topco Ltd boosted its stake in RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after purchasing an additional 18,525 shares during the period. Bleichroeder LP grew its position in RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after purchasing an additional 61,379 shares during the last quarter. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx in the fourth quarter valued at approximately $212,000. Citadel Advisors LLC acquired a new stake in shares of RenovoRx in the third quarter valued at approximately $154,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of RenovoRx during the second quarter valued at approximately $98,000. Institutional investors and hedge funds own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RNXT. Ascendiant Capital Markets lifted their price objective on shares of RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, April 9th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of RenovoRx in a research report on Wednesday, April 8th. Wall Street Zen lowered shares of RenovoRx from a “hold” rating to a “strong sell” rating in a report on Saturday, April 4th. Finally, JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.